Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Linda C. Stork"'
Autor:
Mignon L. Loh, Alison M. Friedmann, David T. Marshall, Nyla A. Heerema, Leonard A. Mattano, Naomi J. Winick, Cindy Wang, Julie M. Gastier-Foster, William L. Carroll, Meenakshi Devidas, Kelly W. Maloney, Andrew J. Carroll, Stephen P. Hunger, Nina S. Kadan-Lottick, Patrick J. Buckley, Michael J. Borowitz, Brent L. Wood, Yousif Matloub, Elizabeth A. Raetz, Linda C. Stork
Publikováno v:
Journal of Clinical Oncology. 39:1540-1552
PURPOSE Children's Oncology Group (COG) AALL0331 tested whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the continuous complete remission (CCR) rate in a low-risk subset of children with standard-risk B-acu
Autor:
David E Kram, Stephanie M Krasnow, Peter R Levasseur, Xinxia Zhu, Linda C Stork, Daniel L Marks
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0168731 (2016)
Steroid-induced sleep disturbance is a common and highly distressing morbidity for children receiving steroid chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL). Sleep disturbance can negatively impact overall quality of l
Externí odkaz:
https://doaj.org/article/d2c625bb497346288cb25cb216d0782d
Autor:
William L. Carroll, Julie M. Gastier-Foster, Nina S. Kadan-Lottick, Patrick J. Buckley, Michael J. Borowitz, Kelly W. Maloney, Elizabeth A. Raetz, Stephen P. Hunger, Linda C. Stork, Alison M. Friedmann, Cindy Wang, Meenakshi Devidas, David T. Marshall, Brent L. Wood, Andrew J. Carroll, Yousif Matloub, Mignon L. Loh, Naomi J. Winick, Nyla A. Heerema, Leonard A. Mattano
Publikováno v:
J Clin Oncol
PURPOSE Children’s Oncology Group (COG) AALL0331 tested whether intensified postinduction therapy that improves survival in children with high-risk B-cell acute lymphoblastic leukemia (ALL) would also improve outcomes for those with standard-risk (
Autor:
Julie M. Gastier-Foster, Eileen Stonerock, Nyla A. Heerema, Lingyun Ji, Naomi J. Winick, Bruce Bostrom, Meenakshi Devidas, Xinxin Xu, Stephen P. Hunger, Linda C. Stork, Karen R. Rabin, Yousif Matloub, Paul S. Gaynon, William L. Carroll, Johann Hitzler
Publikováno v:
Blood Advances. 3:1647-1656
The Children’s Cancer Group 1991 study was a clinical trial for children with National Cancer Institute standard-risk acute lymphoblastic leukemia (ALL). This trial demonstrated that 5 doses of vincristine and escalating IV methotrexate (MTX) witho
Autor:
Leonard A, Mattano, Meenakshi, Devidas, Kelly W, Maloney, Cindy, Wang, Alison M, Friedmann, Patrick, Buckley, Michael J, Borowitz, Andrew J, Carroll, Julie M, Gastier-Foster, Nyla A, Heerema, Nina S, Kadan-Lottick, Yousif H, Matloub, David T, Marshall, Linda C, Stork, Mignon L, Loh, Elizabeth A, Raetz, Brent L, Wood, Stephen P, Hunger, William L, Carroll, Naomi J, Winick
Publikováno v:
J Clin Oncol
Children's Oncology Group (COG) AALL0331 tested whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the continuous complete remission (CCR) rate in a low-risk subset of children with standard-risk B-acute lymph
Publikováno v:
Pediatr Blood Cancer
Background Within pediatric oncology, parental decision making regarding participation in clinical trials that aim to reduce therapy to mitigate side effects is not well studied. The recently completed Children's Oncology Group trial for standard-ris
Autor:
O. John Ma, Denise Langley, Beech Burns, Erin Burns, Linda C. Stork, Amber Lin, Melinda Hartenstein, James A. Heilman, Mary Tanski
Publikováno v:
Pediatric Quality & Safety
Introduction: Febrile neutropenia is a potentially life-threatening complication of chemotherapy in pediatric oncology patients. Prompt initiation of antibiotic therapy may minimize morbidity and mortality associated with this condition, and time to
Autor:
Linda C. Stork, Judy Felgenhauer, Rima Jubran, Kathleen M. Sakamoto, Caroline Hastings, Patrick A. Zweidler-McKay, Judith F. Margolin, Mona D. Shah, Janet Franklin, Suman Malempati, Jacqueline Casillas, George R. Buchanan, Mary Jane Staba Hogan, Joanne M. Hilden, Sarah R. Vaiselbuh, Vandy Black, James Harper, Nita L. Seibel
Publikováno v:
Pediatric Blood & Cancer. 63:1723-1730
Autor:
Lara E. Davis, Jillian Paxton, Christopher W. Ryan, Joseph S. Bubalo, Brittany Wippel, Kenneth R. Gundle, Rongwei Fu, Theresa Dang, Linda C. Stork
Publikováno v:
Cancer Medicine
Background Doxorubicin, cisplatin, and high‐dose methotrexate (HDMTX) are the backbone of pediatric osteosarcoma treatment. However, due to toxicity concerns and the lack of data regarding efficacy in adults, high‐dose methotrexate is rarely used
Autor:
Rene Swanink, Landman Parker Judith, Mariana Sacchi, Rocio Cardenas Cardos, Jong Jin Seo, Pamela Kearns, Franca Fagioli, Linda C. Stork, Carmino Antonio De Souza, Karen R. Rabin, Yves Bertrand, Donna Lancaster, Tapan Saikia, Nack Gyun Chung, Maria Lucia de Martino Lee, Nobuko Hijiya, C. Michel Zwaan, Andrew E. Place, Lia Gore
Publikováno v:
Journal of Clinical Oncology, 36(13), 1330-1338. American Society of Clinical Oncology
Purpose Safe, effective treatments are needed for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP). Dasatinib is approved for treatment of adults and children with CML-CP. A phase I study determined suitable dosing for child
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e26e97dd33bf996fef2e0993068c3766
https://europepmc.org/articles/PMC5929218/
https://europepmc.org/articles/PMC5929218/